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Abstract: The physiological role of the renin angiotensin aldosterone system (RAAS) is to 
maintain the integrity of the cardiovascular system. The effect of angiotensin II is mediated via 
the angiotensin type I receptor (AT1) resulting in vasoconstriction, sodium retention and myocyte 
growth changes. This causes myocardial remodeling which eventually leads to left ventricular 
hypertrophy, dilation and dysfunction. Inhibition of the RAAS with angiotensin converting 
enzyme (ACE) inhibitors after acute myocardial infarction has been shown to reduce cardio-
vascular morbidity and mortality. Angiotensin receptor blockers (ARBs) speciﬁ  cally inhibit 
the AT1 receptor. It has not been known until the performance of the VALIANT (valsartan in 
acute myocardial infarction trial) whether blockade of the angiotensin receptor with an ARB 
or combination of an ACE inhibitor and ARB leads to similar outcomes as an ACE inhibitor. 
The VALIANT trial demonstrated equal efﬁ  cacy and non-inferiority of the ARB valsartan 160 
mg bid compared with captopril 50 mg tds, when administered to high risk patients with left 
ventricular dysfunction or heart failure in the immediate post myocardial infarction period. 
The combination therapy showed no incremental beneﬁ  t over ACE inhibition or an ARB alone 
and resulted in increased adverse effects. This review examines the role of valsartan in left 
ventricular dysfunction post myocardial infarction. We also discuss pharmacokinetics, dosing, 
side effects, and usage in the elderly.
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Introduction
The renin angiotensin aldosterone system (RAAS) is an endocrine system, which 
generates an effector hormone called angiotensin II. The effects of angiotensin 
II are mediated through its stimulation of AT1 and AT2 receptors. Angiotensin 
receptor blockers (ARBs) and angiotensin converting enzyme (ACE) inhibi-
tors are antagonists of the RAAS recommended for use in the management of 
patients with heart failure post myocardial infarction (Antman et al 2004). The 
2004 American college of cardiology/American heart association (ACC/AHA) 
gave ARBs a Class I recommendation in patients who were intolerant of ACE 
inhibitors and who had an acute myocardial infarction with an left ventricular 
ejection fraction less than 40% or clinical (or radiological) evidence of heart 
failure (Antman et al 2004).
Renin angiotensin aldosterone system (RAAS)
The RAAS is responsible for maintaining the integrity of the cardiovascular system 
(see Figure 1). The ACE catalyzes the conversion of angiotensin I to angiotensin II. 
Homeostasis of sodium and the extracellular ﬂ  uid volume as well as vasoconstriction 
occur through direct action of angiotensin II on the AT1 (angiotensin I) receptor. In 
addition the ACE is also responsible for the degradation of bradykinin which is a potent 
vasodilator (Goodfriend et al 1996). Stimulation of the AT2 receptor has also been Vascular Health and Risk Management 2007:3(4) 426
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shown to induce vasodilation and natriuresis (Goodfriend et 
al 1996). This effect is in contrast to stimulation of the AT1 
receptor which causes vasoconstriction and sodium retention. 
In heart failure a vicious cycle prevails in which the RAAS 
activity is increased. This results in increased angiotensin II 
that perpetuates vasoconstriction, left ventricular hypertro-
phy, endothelial dysfunction, and myocardial remodeling 
(see Table 1). Aldosterone and catecholamine increases also 
maintain hemodynamics.
ACE inhibitors work by inhibiting kininase II and degradation 
of bradykinin which results in elevated levels of bradykinin. 
Increased bradykinin leads to vasodilation via the release of 
endothelial nitric oxide but is also responsible for ACE inhibitor 
intolerance with cough. ARBs act by a different mechanism 
than ACE inhibitors by blocking the binding of angiotensin II 
to the AT1 receptor (Goodfriend et al 1996). The production of 
angiotensin II is unaffected. Bradykinin is metabolized in its 
normal fashion and this may at least partly explain the lower 
frequency of cough than with ACE inhibitors.
Angiotensin II may be generated by intramyocardial 
tissue angiotensin converting enzyme pathways (tissue ACE) 
or non-ACE pathways (chymase), which are not inhibited by 
ACE inhibitors (Colucci 2006).
ARBs have beneﬁ  cial effects by blocking the AT1 receptor 
in heart failure. The effect of heart failure on the AT1 receptor 
is down-regulation and reduced gene expression. This results 
in enhanced local activity of angiotensin II (Haywood et al 
1997; Asano et al 2006). Increased ACE activity and intra-
myocardial ACE binding sites have been demonstrated 
in heart failure (Zisman et al 1998). The intra-myocardial 
renin angiotensin system may be an important mechanism 
for the development of left ventricular hypertrophy and 
ventricular dilation producing the myocardial remodeling 
that accompanies heart failure (Dzau 1993).
ACE inhibitor use post myocardial infarction is associated 
with stabilization of heart size and delayed progression in the 
remodeling that results in systolic and diastolic dysfunction 
(Mitchell et al 1882; Hayashida et al 1993). ACE inhibitors 
have been shown to retard the progression of heart failure, 
improve survival, and reduce ventricular remodeling post 
myocardial infarction (Rutherford et al 1994; Pfeffer 1995; 
Hunt et al 2001). ACE inhibitors in patients with myocardial 
infarction also reduce the occurrence of cardiovascular events 
in high-risk patients with signs of heart failure (Pfeffer et al 
2003). International guidelines recommend ACE inhibitors 
as ﬁ  rst-line therapy (Hunt et al 2001).
Figure 1 The renin angiotensin aldosterone system. Reproduced with permission from McMurray JJ, Pfeffer MA, Swedberg K, et al. 2004. Which inhibitor of the renin-
angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation, 110:3281–8. Copyright © 2004. Massachusetts Medical Society. All 
rights reserved.
Table 1 The effects of angiotensin II on the heart in left ven-
tricular dysfunction
Potent vasoconstriction
Sympathetic nervous system activation
Vasopressin release
Endothelin activation
Platelet aggregation
Thrombosis due to increased plasminogen activator inhibitor-1 (PAI-1)
Myocardial remodeling
 –myocyte  hypertrophy
 –collagen  deposition
Aldosterone releaseVascular Health and Risk Management 2007:3(4) 427
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Angiotensin receptor blocker versus 
ACE inhibitor
ARBs have been shown to be as effective as ACE inhibi-
tors in the management of hypertension, congestive heart 
failure and chronic renal failure (McMurray et al 2003). 
However, there are fundamental differences between these 
two classes of drugs. In addition to the differential effect of 
kinins, inhibition of angiotensin II formation with an ACE 
inhibitor diminishes the activity of both the AT1 and AT2 
receptors. ARBs selectively block AT1 receptor activity 
with no blocking effect on the AT2 receptor. The blockade 
of AT1 receptor results in enhanced stimulation of the AT2 
receptor. Further cardiovascular protection may be afforded 
from the enhanced AT2 receptor activity via vasodilation and 
ﬁ  brinolytic mechanisms (Horiuchi et al 1999).
The Val-HeFT trial evaluated the addition of valsartan 
to standard therapy for congestive heart failure, including 
ACE inhibitors. There was a signiﬁ  cant reduction in the 
risk of hospital admissions for worsening heart failure, and 
death, in this cohort with the use of valsartan (Cohn and 
Tognoni 2001). In a subset analysis, 366 patients who were 
not receiving ACE inhibitors were randomly assigned to 
either valsartan or placebo. At approximately 2 years, val-
sartan signiﬁ  cantly reduced both all-cause mortality (17% 
vs 27%, p = 0.01) and a combined mortality and morbidity 
end point (25% vs 43%, p <0.001) (Maggioni et al 2002). 
Patients in the Val-HeFT trial treated with valsartan had a 
smaller rise in serum noradrenalin than those treated with 
placebo (12 vs 41 pg/mL) (Latini et al 2002).
The efﬁ  cacy and safety of ARBs in acute myocardial 
infarction has recently been evaluated with the ARB losartan 
in the optimal trial in myocardial infarction with the angio-
tensin II antagonist losartan (OPTIMAAL) trial in patients 
with myocardial infarction with the angiotensin II antagonist 
losartan and valsartan in the valsartan in acute myocardial 
infarction trial (VALIANT) trials (Pfeffer et al 2000, 2003). 
In the OPTIMAAL trial the effects of losartan (50 mg per 
day) were compared with the ACE inhibitor captopril (50 
mg 3 times per day) for morbidity and mortality after acute 
myocardial infarction. The results showed a non-signiﬁ  cant 
difference in total mortality in favor of captopril. It is 
important to note that in this particular trial a sub-optimal 
dose of losartan was used and may have been responsible for 
the apparent inferiority of losartan (Dickstein et al 2002).
VALIANT was a double blinded, multicenter international 
trial that compared treatment with valsartan alone, or in com-
bination with captopril (Pfeffer et al 2000, 2003). The target 
dose of valsartan was 160 mg twice daily. The cohort included 
high risk patients with evidence of systolic dysfunction or heart 
failure 12 hours to 10 days post myocardial infarction and were 
followed up for 2 years. The results showed equal efﬁ  cacy  of 
valsartan monotherapy versus captopril monotherapy. Valsar-
tan was neither superior nor inferior to captopril for the primary 
endpoint of mortality: 19.5% captopril vs 19.9% valsartan 
(hazard ration [HR] = 1.00; 97.5%, conﬁ  dence interval [CI] 
0.90–1.11; p = 0.98); and the composite end point of cardio-
vascular death, myocardial infarction, and heart failure in the 
valsartan group as compared with the captopril group was 
close to one (Pfeffer et al 2003) (HR = 0.96; p = 0.198). The 
combination showed no beneﬁ  cial effects and was associated 
with more adverse effects (see next section).
Cough, rash, and taste disturbance were more common 
in the captopril group. Angioedema was infrequent and did 
not differ among the groups (Figure 3).
The combination showed no beneﬁ  cial effects and was 
associated with more adverse effects (see next section).
A recent analysis of the VALIANT trial shows that 
valsartan was as effective as captopril in decreasing the fre-
quency of atherosclerotic events such as fatal and non-fatal 
myocardial infarction, angina, revascularization, and stroke 
(McMurray et al 2003).
Angiotensin receptor blocker–ACE 
inhibitor combination therapy
The intramyocardial enzymatic pathway may produce angio-
tensin II through a mechanism that bypasses the effects of 
ACE inhibitors. This alternative pathway using myocardial 
chymase is upregulated in heart failure (Menard et al 1997). 
Angiotensin II mediates its activity via the AT1 receptor, 
which is selectively blocked by ARBs. Combined treatment 
with an ACE inhibitor and an ARB may therefore block more 
efﬁ  ciently the effects of angiotensin II (Menard et al 1997).
In an animal study of heart failure produced by rapid atrial 
pacing, the ACE inhibitor benazipril resulted in improvement 
in myocyte beta-adrenergic response with reduction in the 
degree of left ventricular dilation, reduction in the levels of 
circulating catecholamines, and improvement in myocyte 
shortening velocity and global ventricular function (Spinale 
et al 1997a, b). The combination of benazipril and valsartan 
resulted in changes in the above parameters that were greater 
than those obtained with ACE inhibition alone. In rats 
combination therapy has been shown to reduce the deleterious 
effects of exercise on post myocardial infarction remodeling 
(Mankad et al 2001). There is therefore a theoretical basis 
for combination therapy to be more effective than either 
class alone.Vascular Health and Risk Management 2007:3(4) 428
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In the VALIANT trial, the valsartan-and-captopril com-
bination group had the most drug-related adverse events and 
did not increase survival nor decrease morbidity compared 
to monotherapy (Figure 2). Combination therapy therefore 
has no current role in the management of patients early post 
myocardial infarction (Pfeffer et al 2003).
Adverse effects in the valsartan group were more com-
mon (compared with the captopril monotherapy group) with 
a higher risk of developing hypotension (15.1% vs 11.9%; 
p < 0.05), renal dysfunction (4.9% vs 3.0%; p < 0.05), and 
hyperkalemia (1.3% vs 0.9%; p = n/s) (Figure 3). Dose re-
ductions and permanent discontinuations of study medication 
for renal causes were more frequent in the valsartan and the 
combination groups.
Valsartan in the elderly
Sizable proportions of patients with myocardial infarction 
are elderly and have a disproportionately high mortality and 
morbidity. The numbers of elderly patients are increasing 
and their outcomes remain poor. In the VALIANT trial age 
was an independent predictor of mortality and heart failure, 
with each 10-year age increase being associated with an HR 
of 1.49 for mortality and an odds ratio (OR) of 1.38 for read-
mission with heart failure (White et al 2005). Hypotension, 
renal dysfunction, and hyperkalemia were more common 
in elderly patients receiving valsartan. Elderly patients had 
good compliance with the study medications but were pre-
scribed lower doses of captopril, valsartan, and combination 
therapy than younger patients. In the doses used, captopril 
and valsartan monotherapy achieved similar mortality and 
morbidity outcomes in elderly patients.
Valsartan doses
In patients with left ventricular dysfunction after myocardial 
infarction the recommended starting dose is 20 mg twice daily 
then titrated to a target of 160 mg twice daily as tolerated. 
This may be initiated in stable patients 12 hours following 
acute myocardial infarction. Close monitoring for hypoten-
sion, hyperkalemia, and renal dysfunction is required.
Pharmacokinetics
Valsartan has a half-life of 6 hours (Chiolero and Burnier 
2006). It is largely protein bound to albumin (95%) and 
undergoes signiﬁ  cant ﬁ  rst pass metabolism in the liver with 
a low bioavailability of approximately 25%. Peak plasma 
levels occur 2 hours after dosing. Valsartan is excreted as 
an inactive metabolite in the feces and less than a ﬁ  fth in 
the urine as unchanged drug. Studies evaluating the phar-
Figure 2 Cardiovascular death, myocardial infarction or heart failure by treatment in the VALIANT trial. Reproduced from Pfeffer MA, McMurray JJV, Velazquez EJ, et al. 
2003. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [Erratum in N Engl J Med, 2004. 350:203]. N Engl J 
Med, 349:1893–906. Copyright © Massachusetts Medical Society. All rights reserved.
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macokinetics of valsartan in elderly patients (over 70 years 
of age) showed decreased plasma clearance and a slightly 
prolonged elimination half-life. Dosing should be carefully 
titrated in the elderly in order to achieve the desired effect 
(Siouﬁ   et al 1998).
Contraindications
There are a number of contraindications to valsartan, includ-
ing hypersensitivity to either valsartan or other angiotensin 
receptor antagonists, bilateral renal artery stenosis, and 
pregnancy. Valsartan must be discontinued once pregnancy 
is detected, as medications that act on the RAAS have a 
number of fetal effects including hypotension, neonatal skull 
hypoplasia, anuria, renal failure, and death.
Precautions with valsartan
During the initiation of therapy, hypotension and hyperka-
lemia may occur, particularly in patients with heart failure 
or post myocardial infarction patients. A small dose should 
be used in patients who are volume depleted with correction 
of the dehydration ﬁ  rst. Deterioration in renal function can 
occur with initiation and renal function should be monitored 
closely especially in patients with severe heart failure. 
Changes in renal function should be anticipated and dosage 
adjustments of valsartan or concomitant medications may 
be needed. Valsartan should be used with caution in patients 
with unilateral renal artery stenosis and pre-existing renal 
insufﬁ  ciency. Initiation of low doses is necessary in low 
output states and low doses are recommended in patients 
with signiﬁ  cant hepatic dysfunction. 
Conclusion
Valsartan is an important addition to the armamentarium of 
drugs that have been shown to be effective in patients with heart 
failure post myocardial infarction. The addition of valsartan to 
ACE inhibitors early after myocardial infarction has no current 
role but valsartan has an important role as an alternative to ACE 
inhibitors when ACE inhibitors are not tolerated.
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